X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA WYETH LTD SHASUN PHARMA/
WYETH LTD
 
P/E (TTM) x 123.9 27.7 447.0% View Chart
P/BV x 8.5 5.3 159.5% View Chart
Dividend Yield % 0.2 1.3 18.3%  

Financials

 SHASUN PHARMA   WYETH LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
WYETH LTD
Mar-13
SHASUN PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs941,044 9.0%   
Low Rs46818 5.6%   
Sales per share (Unadj.) Rs214.2298.6 71.7%  
Earnings per share (Unadj.) Rs5.357.2 9.3%  
Cash flow per share (Unadj.) Rs15.858.4 27.1%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %1.41.8 78.4%  
Book value per share (Unadj.) Rs53.3249.5 21.4%  
Shares outstanding (eoy) m56.6222.72 249.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 10.5%   
Avg P/E ratio x13.116.3 80.5%  
P/CF ratio (eoy) x4.415.9 27.7%  
Price / Book Value ratio x1.33.7 35.1%  
Dividend payout %18.729.7 63.1%   
Avg Mkt Cap Rs m3,95821,157 18.7%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m2,164400 540.9%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m12,1276,783 178.8%  
Other income Rs m229353 65.0%   
Total revenues Rs m12,3567,136 173.2%   
Gross profit Rs m1,0091,617 62.4%  
Depreciation Rs m59427 2,231.6%   
Interest Rs m4156 7,547.3%   
Profit before tax Rs m2301,938 11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m-73632 -11.5%   
Profit after tax Rs m3021,301 23.2%  
Gross profit margin %8.323.8 34.9%  
Effective tax rate %-31.732.6 -97.0%   
Net profit margin %2.519.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m6,8846,984 98.6%   
Current liabilities Rs m8,4562,056 411.3%   
Net working cap to sales %-13.072.6 -17.8%  
Current ratio x0.83.4 24.0%  
Inventory Days Days6299 62.1%  
Debtors Days Days10824 449.3%  
Net fixed assets Rs m4,970244 2,034.5%   
Share capital Rs m113227 49.9%   
"Free" reserves Rs m2,8755,441 52.8%   
Net worth Rs m3,0205,668 53.3%   
Long term debt Rs m1,81725 7,269.6%   
Total assets Rs m13,3477,901 168.9%  
Interest coverage x1.6353.3 0.4%   
Debt to equity ratio x0.60 13,642.8%  
Sales to assets ratio x0.90.9 105.8%   
Return on assets %5.416.5 32.5%  
Return on equity %10.022.9 43.6%  
Return on capital %13.334.0 39.1%  
Exports to sales %46.40.2 21,246.6%   
Imports to sales %14.236.3 39.2%   
Exports (fob) Rs m5,62215 37,983.1%   
Imports (cif) Rs m1,7282,465 70.1%   
Fx inflow Rs m5,84315 38,438.2%   
Fx outflow Rs m2,1732,677 81.2%   
Net fx Rs m3,669-2,662 -137.8%   
CASH FLOW
From Operations Rs m398923 43.1%  
From Investments Rs m-1,635317 -515.9%  
From Financial Activity Rs m1,309-481 -272.1%  
Net Cashflow Rs m71759 9.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 7.2 244.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 30.4 130.3%  
Shareholders   20,750 21,978 94.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Metal Stocks Witness Selling(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.23% while the Hang Seng is down 0.49%. The Nikkei 225 is trading down by 0.55%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS